Marvel Biosciences Corp. (MRVL.V)
- Newsfile
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study ...
- Newsfile
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model (FMR1) of Fragile X syndrome (FXS). Autism and FXS are closely related, often sharing clinical symptoms (e.g., developmental delays, challenges in so
- Newsfile
Marvel Biosciences Announces Stock Option Grants
Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce that, effective July 23, 2024, its board of directors approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,475,000 common shares in the capital of the Company at an exercise price of $0.125, being the closing price ...
